Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.37 |
| ▸ | GCGR | P47871 | 5/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.37 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.37 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2650426 | 0.84 | GCGR (0.43) | BRD4GCGRPTGER1PTGER4PTGER3 | |
| SCHEMBL2648946 | 0.83 | GCGR (0.44) | GCGR | |
| SCHEMBL2647364 | 0.80 | GCGR (0.42) | BRD4GCGRMCL1 | |
| SCHEMBL2648040 | 0.80 | GCGR (0.42) | BRD4GCGRMCL1 | |
| SCHEMBL2650233 | 0.79 | PPIA (0.40) | BRD4PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL2650231 | 0.79 | PPIA (0.40) | BRD4PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL2647675 | 0.77 | GCGR (0.47) | BRD4GCGR | |
| SCHEMBL2654624 | 0.76 | GCGR (0.49) | GCGR | |
| SCHEMBL16253815 | 0.73 | GCGR (0.61) | GCGR | |
| SCHEMBL2647951 | 0.73 | GCGR (0.42) | BRD4GCGRPTGER1PTGER4PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6218431-B1 | GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES | BAYER CORPORATION | 2001-04-17 | — | — | US | disclosed |